NeuroPace Announces Proposed Public Offering of $65 Million of Common Stock

Core Viewpoint - NeuroPace, Inc. plans to offer $65 million in common stock through an underwritten public offering, with a potential additional 15$65 million worth of common stock, all offered by NeuroPace [1]. - NeuroPace will grant underwriters a 30-day option to purchase up to an additional 15% of the shares [1]. - The offering is subject to market conditions, and there is no assurance regarding its completion or terms [1]. Group 2: Use of Proceeds - A significant portion of the proceeds will be used to repurchase shares held by KCK Ltd. at the same price per share as the public offering [2]. - Remaining net proceeds will be allocated for general corporate purposes, including clinical trials, research and development, administrative expenses, debt reduction, and working capital [2]. Group 3: Management and Registration - J.P. Morgan, Cantor, Wells Fargo Securities, and Leerink Partners are joint book-running managers for the offering, with Lake Street Capital Markets as the lead manager [3]. - The shares are being offered under a shelf registration statement effective since November 22, 2022, with a prospectus supplement to be filed with the SEC [4]. Group 4: Company Overview - NeuroPace is a medical device company based in Mountain View, California, focused on improving the lives of epilepsy patients through its RNS System, which provides personalized, real-time treatment [6].